# KYNB catalysts: KYNTRA BIO, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/kynb/catalysts

> KYNTRA BIO, INC. (KYNB) has 4 upcoming catalysts. The next is the FG-3246 topline data readout, Mar to Jun 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | KYNTRA BIO, INC. |
| Ticker | KYNB (Nasdaq) |
| SEC CIK | 921299 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/kynb |

## Cash runway

Cash $95.3M as of 2026-06-30; quarterly burn $4.0M; about 71.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-349183).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2023 | [Evrenzo® (roxadustat) topline data readout](https://sec-api.dev/pdufa/roxadustat) | KYNB |  | completed, positive | "In May 2023, we announced positive topline data from our Phase 3 clinical study of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies in China." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921299/000095017024125388/fgen-20240930.htm)) |
| May 2024 | [FG-3246 interim data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | completed, positive | "In May 2024, the University of California, San Francisco ("UCSF") presented positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with mCRPC at the 2024 American Society of Clinical Oncology Annual Meeting." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921299/000119312525274241/fgen-20250930.htm)) |
| November 12, 2024 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm)) |
| Q1 2025 | [FG-3246 trial start](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | scheduled | "Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm)) |
| 1H 2025 | [FG-3246 topline data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | scheduled | "Topline results from the Phase 2 portion of the investigator-sponsored Phase 1b/2 study conducted by UCSF of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 1H 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm)) |
| March 12, 2025 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-ex99_1.htm)) |
| May 12, 2025 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm)) |
| August 11, 2025 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-ex99_1.htm)) |
| Q4 2025 | [FG-3246 trial start](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC, along with the exploratory analysis of FG-3180 | scheduled | ""With a rejuvenated capital structure, we are on track to commence the Phase 2 monotherapy trial of FG-3246 in mCRPC imminently as well as submit the Phase 3 protocol for roxadustat in anemia associated with lower-risk MDS in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025112341/fgen-ex99_1.htm)) |
| Q4 2025 | [FG-3180 topline data readout](https://sec-api.dev/pdufa/fg-3180) | KYNB |  | scheduled | "We expect topline results from the Phase 2 portion of this study, including data on the CD46 targeted PET imaging agent FG-3180, in the fourth quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921299/000095017025106549/fgen-20250630.htm)) |
| Q4 2025 | [FG-3246 topline data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | scheduled | "Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 4Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-ex99_1.htm)) |
| November 10, 2025 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-ex99_1.htm)) |
| Q1 2026 | [FG-3246 topline data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | mCRPC | scheduled | "Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected to be presented at a medical conference in 1Q 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-ex99_1.htm)) |
| Q1 2026 | [Xtandi (enzalutamide) topline data readout](https://sec-api.dev/pdufa/enzalutamide) | KYNB |  | scheduled | "We expect topline results from the Phase 2 portion of this study in the first quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921299/000119312525274241/fgen-20250930.htm)) |
| March 16, 2026 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-ex99_1.htm)) |
| May 11, 2026 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-ex99_1.htm)) |
| 2H 2026 | [FG-3180 interim data readout](https://sec-api.dev/pdufa/fg-3180) | KYNB |  | scheduled | "Notably, we initiated the Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis anticipated in the second half of 2026," said Thane Wettig, Chief Executive Officer, FibroGen." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-ex99_1.htm)) |
| August 13, 2026 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-ex99_1.htm)) |
| Q4 2026 | [Evrenzo® (roxadustat) trial start](https://sec-api.dev/pdufa/roxadustat) | KYNB | anemia in patients with LR-MDS | scheduled | "Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-ex99_1.htm)) |
| Q4 2026 | [FG-3246 interim data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | with mCRPC | scheduled | "Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-ex99_1.htm)) |
| Mar to Jun 2028 | [FG-3246 topline data readout](https://sec-api.dev/pdufa/fg-3246) | KYNB | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06842498 (A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842498)) |
| March 2028 | [FG-3246 primary completion](https://sec-api.dev/pdufa/fg-3246) | KYNB | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06842498 (A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842498)) |
| September 2030 | [Evrenzo® (roxadustat) primary completion](https://sec-api.dev/pdufa/roxadustat) | KYNB | Myelodysplastic Syndromes | scheduled | "NCT07722988 (A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722988)) |
| Sep to Dec 2030 | [Evrenzo® (roxadustat) topline data readout](https://sec-api.dev/pdufa/roxadustat) | KYNB | Myelodysplastic Syndromes | scheduled | "NCT07722988 (A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722988)) |

## Drugs

- [Xtandi (enzalutamide)](https://sec-api.dev/pdufa/enzalutamide): 
- [FG-3180](https://sec-api.dev/pdufa/fg-3180): 
- [FG-3246](https://sec-api.dev/pdufa/fg-3246): mcrpc, with mcrpc, mcrpc, along with the exploratory analysis of fg-3180, metastatic castration-resistant prostate cancer, with interim results, mcrpc, currently, mcrpc in mid-2025, Metastatic Castration-Resistant Prostate Cancer
- [Evrenzo® (roxadustat)](https://sec-api.dev/pdufa/roxadustat): anemia in patients with lower-risk myelodysplastic syndromes, anemia in patients with lr-mds, Myelodysplastic Syndromes

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/kynb/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KYNB catalysts: KYNTRA BIO, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/kynb/catalysts

```bibtex
@misc{secapidev_companies_kynb_catalysts_20261116,
  title        = {KYNB catalysts: KYNTRA BIO, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/kynb/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_kynb_catalysts_20261116","title":"KYNB catalysts: KYNTRA BIO, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/kynb/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
